Background: The two front-line drugs for chronic Trypanosoma cruzi infections are limited by adverse side-effects and declining efficacy. One potential new target for Chagas' disease chemotherapy is sterol 14a-demethylase (CYP51), a cytochrome P450 enzyme involved in biosynthesis of membrane sterols.
Introduction
The drug development pipeline targeting diseases caused by trypanosome parasites is sparse [1] . Despite significant advances in its control over the last 15 years [2] , Chagas' disease, caused by the parasitic protozoan Trypanosoma cruzi [3] , remains a major public health concern in Latin America, with an estimated total of 8 million people infected [4] . Nifurtimox and benznidazole, the two principal drugs for treatment of Chagas' disease, were launched in 1967 and 1972 respectively, and suffer from the twin liabilities of serious side-effects and reduced efficacy in chronic T. cruzi infections [2] . A potential new target for Chagas' disease chemotherapy is sterol 14a-demethylase (CYP51) [5] , a cytochrome P450 heme thiolate-containing enzyme which is involved in biosynthesis of membrane sterols in all biological kingdoms from bacteria to animals [6] . T. cruzi sterols are similar in composition to those in fungi, with ergosterol and ergosterol-like sterols the major membrane components [7] . Clinically employed antifungal azoles [8, 9] inhibit ergosterol biosynthesis in fungi and are partially effective against Leishmania and Trypanosoma parasites [10] [11] [12] . Azoles block CYP51 activity, resulting in decline of the normal complement of endogenous sterols and accumulation of various 14a-methyl sterols with cytostatic or cytoxic consequences [11] . Aside from the compounds optimized for antifungal therapy, other CYP51 inhibitors with strong anti-T. cruzi activity have also been reported [13] [14] [15] .
Mammalian CYP51 shares relatively modest overall sequence identity -below 30% -with its fungal and protozoan counterparts, but within the active site the amino acid residues are far more conserved. Based upon crystal structures of CYP51 of M. tuberculosis (CYP51 Mt ) [16] [17] [18] [19] [20] , three of the thirteen active site residues, Y76, F83, and H259 (numbering according to CYP51 Mt ), are invariant throughout the cyp51 gene family. Two residues, F78 and F255, are specific to the methylation status of the C-4 atom in the sterol nucleus [18, 21] , and amino acid identities of seven other positions strongly overlap across phyla [19, 20] . Of the thirteen residues, only one, R96, seems to be phylum-specific. This similarity confines design of selective CYP51 inhibitors to a species-specific cavity in the active site defined by the hydrophobic residues F78, L321, I322, I323, M433, and V434.
To discover novel inhibitors, we previously screened a library of small synthetic molecules against the CYP51 Mt target [19] . The N-[4-pyridyl]-formamide moiety of the top hit, a-ethyl-N-4-pyridinyl-benzeneacetamide (EPBA), was found to bind unvaryingly in the CYP51 active site with Y76, H259, and the heme prosthetic group. The uniformity of interactions with CYP51 suggested that this scaffold could be used to target a variety of chemotypes to the active site. To verify this assumption, we determined the binding modes of second generation compounds containing the N-[4-pyridyl]-formamide moiety by determining their co-crystal structures with CYP51 Mt . We also spectrally characterized binding of these compounds to CYP51 of both T. cruzi (CYP51 Tc ) and the related protozoan parasite T. brucei, the causative agent of African sleeping sickness, (CYP51 Tb ). Two compounds were selected based on their nanomolar binding affinities toward CYP51 Tc and subsequently tested in vitro for inhibitory effects against both pathogens. One of the two compounds revealed potent and selective inhibitory effect against T. cruzi infection in mouse macrophage cells.
Methods

Preparation of CYP51 Mt
CYP51 Mt double C37L/C442A and triple C37L/F78L/C442A mutants were prepared as described elsewhere [19] . The surface exposed cystein residues C37 and C442 were removed via replacement with leucine and alanine, respectively, to improve protein homogeneity and aid crystallization [18] . The functionally important F78 in the active site was replaced in the triple mutant by leucine, which invariantly occupies this position in the mammalian CYP51 isoforms.
Preparation of CYP51 Tc
Design of the CYP51 Tc expression vector was based on an entity in the NCBI data bank (ID AY283022 [22] ), which was modified by replacing the first 31 residues upstream of Pro32 with the fragment MAKKTSSKGKL from the CYP2C3 sequence [23] (CYP2C3 residues marked in bold) to improve protein solubility, and by inserting a His 6 -tag at the C-terminus to facilitate purification. This coding sequence (kindly provided by M. Waterman in the form of the pET vector) was subsequently subcloned into pCWori vector [24] between the NdeI and HindIII restriction sites and in this form used to transform Escherichia coli strain HMS174(DE3).
Transformants were grown for 5 h at 37uC and 250 rpm agitation in Terrific Broth medium supplemented with 1 mM thiamine, 50 mg/ml ampicillin, and trace elements. CYP51 Tc expression was induced by the addition of isopropyl-b-Dthiogalactopyranoside (IPTG, final concentration 0.2 mM) and d-aminolevulinic acid, a precursor of heme biosynthesis (final concentration 1 mM). Following induction, temperature was decreased to 25uC and agitation to 180 rpm. After 30 hours the cells were harvested and lysed by sonication. Insoluble material was removed from crude extract by centrifugation (30 min at 35,000 rpm). The supernatant was subjected to a series of chromatographic steps, including nickel-nitrilotriacetic acid (Ni-NTA) agarose (QIAGEN), followed by Q-Sepharose (Amersham Biosciences) in the flow-through regime, and then by S-Sepharose (Amersham Biosciences). From the S-Sepharose, protein was eluted in a 0.2 to 1.0 M NaCl gradient and observed by means of a 12% SDS-PAGE to be virtually homogeneous. Fractions containing P450 were combined, concentrated using a Centriprep concentrating device (Millipore), and stored at 280uC. Twenty mM Tris-HCl, pH 7.5, 10% glycerol, 0.5 mM EDTA, and 1 mM DTT were maintained throughout all chromatographic steps. Spectral characteristics of CYP51 Tc are shown in Figure 1A .
Preparation of CYP51 Tb
The expression vector for CYP51 Tb (ID EAN79583) was generated using T. brucei genomic DNA and upsteam GCGCGCATATGGCTCTTGAAGTTGCC and downstream CGCAAGCTTCTAGTGATGGTGATGGTGATGGTGATGA-GCAGCTGCCGCCTTCC primers. The underlining denotes an NdeI restriction cloning site in the upstream primer and the HindIII restriction cloning site in the downstream primer followed by the stop codon. The bold sequence in the upstream primer highlights second codon replaced with alanine to optimize expression in E. coli cells [24] . The boldface in the downstream primer indicates the His 8 tag. The original genomic DNA contained internal NdeI site at 345 base pair which was removed by introducing a silent mutation via the quick-change mutagenesis protocol (Stratagene). DNA amplification reaction was carried out as follows: 5 min at 94uC, annealing for 1 min at 55uC, and extension for 1 min at 72uC, for 30 cycles, followed by extension for 10 min at 72uC. The purified 1.5 kb PCR product was ligated into the pCR 2.1 TA cloning vector (Invitrogen). Insert was subsequently cleaved with NdeI and HindIII and ligated into pCWori vector digested with the same restriction enzymes and treated with alkaline phosphatase. The identity of the resulting vector was confirmed by DNA sequencing.
E. coli HMS174(DE3) strain was co-transformed with this vector and the pGro7 plasmid (Takara) encoding the E. coli chaperones GroES and GroEL. Double transformants were selected on agar plates containing both ampicilin and chloramphenicol. One liter of Terrific Broth medium supplemented with 1 mM thiamine, 100 mg/ml ampicillin, 40 mg/ml chloramphenicol, and trace
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Crystallization, Data Collection, and Determination of Crystal Structure
Five compounds (Fig. 2) , purchased from ChemDiv (San Diego, California) were used for co-crystallization with the CYP51 Mt C37L/C442A double mutant. Compared to the wild type, this construct has superior propensity for crystallization. Compound numbering is according to the order in which they were received in our laboratory, with number 7 being the first used in the current work. Ligands were dissolved in Me 2 SO at #100 mM stock concentration, and brought to final concentrations ranging from 1 to 5 mM in the crystallization mix, depending on ligand solubility. Protein concentration was 0.2 mM. A narrow crystallization screening grid (15-30% PEG 4000, 2-12% isopropanol, 0.1 M HEPES, pH 7.5), previously devised to obtain CYP51 Mt crystals [16, 18, 19] was utilized for co-crystallization of complexes by the vapor diffusion hanging drop method. Four co-crystal forms were obtained, all diffracted to resolutions between 1.56 to 1.60 Å . Diffraction data were collected at 100-110 K at the Southeast Regional Collaborative Access Team (SER-CAT) 22ID beamline, Advanced Photon Source, Argonne National Laboratory using SER-CAT mail-in data collection program ( Table 1 ). The images were integrated and the intensities merged with the HKL2000 software suite [25] . The structures were determined by molecular replacement using coordinates of estriol-bound CYP51 Mt (Protein Data Bank ID 1X8V) as a search model. The final atomic models were obtained after a few iterations of refinement using REFMAC5 [26] and model-building using the COOT graphics modeling program [27] . The quality of the structures was assessed by the program PROCHECK [28] . One residue, A46, was found in the generously allowed region of the Ramachandran plot in all structures where, together with the adjacent G47, it enables a sharp turn between two b strands.
Spectroscopic Binding Assays
Spectroscopic binding assays were performed at room temperature in 1-ml quartz cuvette containing 1 mM or 2 mM CYP51 in 50 mM Tris-HCl, pH 7.5, and 10% glycerol using a Cary UVvisible scanning spectrophotometer (Varian). Concentration of CYP51 was determined at 450 nm from the difference spectra between the carbon monoxide-bound ferrous and water-bound ferric forms, with an extinction coefficient of 91,000 M 21 cm 21 [29] . In the first round, compounds dissolved in Me 2 SO at 10 mM concentration were added to the 2 mM protein solution in 0.5 ml aliquots, resulting in concentration increases from 5 mM to 50 mM in 5 mM increments. The same amounts of Me 2 SO alone were added to the protein in the reference cuvette, followed by recording the difference spectra. In the second round, compounds with high affinities were diluted to 100 mM by Me 2 SO and titrated into 1 mM protein solution in 1 ml aliquots to increase compound concentration from 0.1 mM to 2 mM in 0.1 mM increments. To determine the K D , we used the GraphPad PRISM software (Graphpad Software Inc.) to fit titration data to either rectangular or quadratic hyperbolas to correct for the bound ligand fraction, according to the functions
, respectively, where E is total enzyme and L total ligand concentration, A max the maximal absorption shift at saturation, and K D the apparent dissociation constant for the enzyme-ligand complex.
T. cruzi Assay
Irradiated (1000 rads) J774 mouse macrophages were plated in 12-well tissue culture plates 24 h prior to infection with 10 5 T. cruzi Y strain trypomastigotes for 2 h at 37uC. Cultures were maintained in RPMI-1640 medium with 5% heat-inactivated fetal calf serum and 5% CO 2 with the addition of 10 mM compound 8 or 10. Untreated controls, controls treated with the inhibitor K11777 (10 mM) [30, 31] , and uninfected macrophage controls were also included. All cultures were in triplicate and medium was replaced every 48 h. Treatment with CYP51 inhibitors continued for up to 27 days. Subsequently, treated cultures were maintained without inhibitor for an additional 13- Rational Design of Anti-T. cruzi CYP51 Inhibitors www.plosntds.org15 days to confirm inhibitor effectiveness and cure of infected cells. Cultures were monitored daily by contrast phase microscopy to determine presence of T. cruzi infected cells and free infectious trypomastigotes (Table 2 ).
IC50
To determine IC50, mouse J774 macrophages were irradiated (1000 rads) to deter growth and plated onto 12-well tissue culture plates. Cells were infected with 10 5 tissue culture trypomastigotes of the Y strain of T. cruzi for 2 h at 37uC, as described above. Next, medium was replaced with the addition of compound 10 at 0, 1 nM, 10 nM, 100 nM, 500 nM, 1 mM, 5 mM, and 10 mM; these cultures were incubated for 52 h at 37uC. Controls with 10 mM K11777 and 10 mM compound 8 were also included. All treatments were performed in triplicate to ensure statistical validity. Cultures were then fixed in 4% paraformaldehyde in PBS for 2 h at room temperature and stained with DAPI (10 nM) in PBS. One hundred cells and their intracellular parasites were quantified as previously described to estimate the mean number of parasites/cell [32] . Mean P/cell data were plotted against compound concentration to estimate the IC50.
Mammalian Cell Toxicity Assay
Toxicity was evaluated in bovine muscle cells (BESM), mouse J774 macrophages, and human Huh7 hepatocytes against compound 10 at 10 mM, 50 mM and 100 mM concentrations. After 48 h in culture at 37uC, cells were stained with 10% Tripan Blue and the number of live versus dead cells was quantified (Table 3) .
T. brucei Assay
Trypanosomes were grown in complete HMI-9 medium containing 10% FBS, 10% Serum Plus medium (Sigma Inc. St. Louis Mo. USA) and 16 penicillin/streptomycin. Trypanosomes were diluted to 1.0610 5 /ml in complete HMI-9 medium. Diluted trypanosomes were aliquoted in Greiner sterile 96-well flat white opaque culture plates using a WellMate cell dispenser (Matrix Tech., Hudson, NH, USA). Compounds 8 and 10 were serially diluted in Me 2 SO. Trypanosomes were incubated with the compounds for 48 h at 37uC with 5% CO 2 before monitoring viability. Trypanosomes were then lysed in the wells by adding 50 ml of CellTiter-GloTM (Promega Inc., Madison, WI, USA). Lysed trypanosomes were placed on an orbital shaker at room temperature for 2 min. The resulting ATP-bioluminescence of the trypanosomes in the 96-well plates was measured at room temperature using an Analyst HT plate reader (Molecular Devices, Sunnyvale, CA, USA).
Results
Crystal Structures of CYP51 Mt -Inhibitor Complexes
Co-crystals were obtained for compounds 8, 9 and 11. Compound 10 failed to generate any crystals with CYP51 Mt . Compound 7 was not found in the CYP51 Mt active site in the Rational Design of Anti-T. cruzi CYP51 Inhibitors www.plosntds.orgcrystal, which is consistent with lack of spectrally detectable binding (Fig. 2 Fig. 2 ) and interactions with the invariant residues Y76 and H259 (Fig. 3) . Functional groups other than the N-[4-pyridyl]-formamide moiety in compounds 9 and 11 either were accommodated in the speciesspecific cavity or else protruded through the opening of the active site toward bulk solvent. H259 hydrogen-bonded to the carbonyl oxygen in both compounds, while interactions with Y76 were mediated by two similarly positioned water molecules (Figs. 3A  and 3B ). The residual F o -F c electron density map suggested two alternative conformations for compounds 11 and 9, designated by pink and cyan respectively in Figures 4A and 4B . In the CYP51 Mtcompound 11 complex, the cyclohexane ring protruded toward the bulk solvent (Fig. 3A) , barely interacting with the protein in two alternative conformations (Fig. 4A) . Together with the limited interactions of the isopropyl moiety, this lack of contact explains the low binding affinity of 11. In the CYP51 Mt -compound 9 complex, the methylcyclohexane moiety protruded toward bulk solvent, while the methylsulfanyl group loosely bound in the species-specific cavity (Fig. 3B ) in two alternative conformations (Fig. 4B) . The side chain of M433 also adopted two alternative conformations. In both complexes, a portion of the BC-region was disordered and missing from the electron density map. Although racemic mixtures were used for co-crystallization, only one enantiomer of each compound was found in the active site.
A different binding mode was revealed for compound 8. Its flexible backbone allowed it to fold head-to-tail over the heme plane to bring the methylphenylsulfonamide group into intramolecular stacking interactions with the pyridinyl moiety and also with the heme macrocycle (Fig. 3C, 4C) . Folding minimized the nonpolar surface of compound 8 by exposing the sulfonamide group to interactions with Q72, K97, and the heme propionate side chain. The hydrophobic side chain of K97 aligned along the methylphenyl moiety. A similar folding of the benzothiadiazolsulfonamide group has been observed in previous work for 2-[(2,1,3-benzothiadiazol-4-sulfonamide]-2-phenyl-N-pyridin-4-acetamide (BSPPA) [19] . Mutually stabilizing protein-ligand interactions involving the BC-loop residues including F78 result in increased binding affinity of the CYP51 Mt -compound 8 complex and in unambiguous electron density both for compound 8 (Fig. 3C) and for the entire BC-region. In the CYP51 Mt -compound 8 complex, H259 directly H-bound to the amide nitrogen of compound 8, whereas Y76 interacted hydrophobically with the compound's flexible backbone (Fig. 3C ).
Binding Affinities of CYP51 Ligands
Binding affinities of all five compounds were examined against both wild type and a 'humanized' F78L mutant form of CYP51 Mt , CYP51 Tc , and CYP51 Tb using spectroscopic assays (Fig. 5) . These assays utilize the property of P450 enzymes to shift the ferric heme iron Soret band following replacement of a weak ligand, the water molecule, with a stronger one, the nitrogen-containing aromatic pyridinyl group (Fig. 5A) . All compounds had markedly reduced or no binding affinity toward CYP51 Mt , compared to the parental EPBA (Fig. 2) . No binding was observed for compound 7, while Rational Design of Anti-T. cruzi CYP51 Inhibitors www.plosntds.orgthe K D for compound 11 exceeded 100 mM, indicating weak binding. However, the binding affinity of all compounds examined, including compound 7, was significantly higher to CYP51 Tc than to CYP51 Mt . Remarkably, the binding affinities of compounds 8 and 10 to CYP51 Tc were 300-and at least 500-fold respectively higher, equaling or exceeding that of the antifungal CYP51 inhibitor fluconazole, which was used as a reference (Fig. 5B, C) . A K D of at least 40 nM was estimated for compound 10 by spectral assays, with the binding curve reaching a plateau at about a 1:1 protein to ligand ratio. This value strongly suggests that the K D must be notably higher, although further dilution of protein in an attempt to obtain a more accurate value significantly decreased the quality of the spectra and this effort was thus abandoned. The IC50 of ,1 nM for T. cruzi intracellular growth inhibition, determined for compound 10 as described below, may better reflect true K D value. Compounds 8 and 10, which had highest binding affinity to CYP51 Tc , were spectrally silent toward CYP51 Tb , indicating no binding in the active site (Fig. 2) . As expected, CYP51 Tb had nanomolar affinity for fluconazole (Fig. 5D ), but again, the plateau was reached at a 1:1 protein to inhibitor ratio, so the binding constant could not be determined more accurately. Compound 9 bound both CYP51 Tc and CYP51 Tb with the same affinity.
The K D values for compounds 8 and 10 slightly decreased for the F78L CYP51 Mt mutant compared to the wild type, while the K D values for the other compounds increased (Fig. 2) .
Inhibitory Effects against T. cruzi
With submicromolar affinities toward CYP51 Tc of 160 nM and ,40 nM respectively, compounds 8 and 10 were examined in vitro for inhibitory effects against both T. cruzi and T. brucei. In a mouse macrophage assay, T. cruzi completed its intracellular development in 5 days in untreated controls, resulting in death of host macrophages and abundant trypomastigotes in culture supernatant ( Table 2 ). As anticipated, the control compound K11777 [30] cured T. cruzi infection. No parasites survived a treatment regime of 27 days with compound 10. Cure of host cells was confirmed by incubation of the cultures for an additional 15 days in the absence of inhibitor. In contrast, and similarly to untreated controls, T. cruzi completed its development in 5 days in cultures treated with compound 8.
An IC50 of ,1 nM concentration for compound 10 ( Fig. 6 ) was estimated for T. cruzi intracellular amastigotes. T. cruzi developed well intracellularly in untreated macrophages with a final mean number of 3.5760.5 P/cell (0% inhibition). As determined previously, 10 mM compound 10 was deleterious for T. cruzi, with a mean of 0.2560.01 P/cell (100% growth inhibition). Ten mM of control compound K11777 was also parasiticidal for T. cruzi with a mean of 0.2560.01 P/cell (IC100) [30] , while compound 8 was not parasiticidal at this concentration with a mean of 1.2260.1 P/cell (data not shown).
Toxicity for mammalian cells was addressed by treating the three different cell types with increasing concentrations of compound 10 (Table 3) . No toxicity was observed at 10 mM compound 10, while 50 mM was mildly toxic for muscle cells. One hundred mM compound 10 was toxic for all mammalian cells tested, especially muscle cells.
Consistent with the spectral binding assays, neither compound 8 nor 10 had any inhibitory effects against cultured T. brucei even at the highest tested concentration of 10 mM. Oxygen atoms are red, nitrogen blue, sulfur yellow. Images were generated using the VMD program [35] . doi:10.1371/journal.pntd.0000372.g003
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Protein Data Bank Accession Numbers
The atomic coordinates and structure factors determined in this study (Protein Data Bank IDs 2W09, 2W0A, and 2W0B) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).
Discussion
We explored sterol 14a-demethylase (CYP51) as a potential target for trypanosomiasis chemotherapy by probing CYP51 Mt , CYP51 Tc , and CYP51 Tc with second generation compounds that contain a universal building block, the N-[4-pyridyl]-formamide moiety, which is capable of delivering small molecule compounds to the CYP51 active site. The affinities of the N-[4-pyridyl]-formamide-derivative compounds that we tested against CYP51 Mt were lower than that of EPBA (Fig. 2) , from which the formamide building block was derived. Affinities of all compounds examined were much higher toward CYP51 Tc than to CYP51 Mt . Strikingly large increases in binding affinities -300 and 500 fold -were observed for compounds 8 and 10. Although compound 10 did not produce crystals with CYP51 Mt , based on the binding modes Rational Design of Anti-T. cruzi CYP51 Inhibitors www.plosntds.orgof compounds 9 and 11, we reason that the methylcyclohexanecarboxamide moiety of compound 10 protrudes toward the BC-loop, suggesting that the indole ring binds in the speciesspecific cavity, including the space occupied in CYP51 Mt by the F78 aromatic ring, which is absent from CYP51 Tc but present in CYP51 Tb and CYP51 Mt . Consistent with this hypothesis, compound 10 selectively bound CYP51 Tc , inhibited T. cruzi growth with the IC50 value close to the K D estimated in the spectral binding assays, and cured mouse macrophages infected with T. cruzi Y strain at 10 mM concentration without harming them.
In contrast, compound 10 failed to bind CYP51 Tb despite the identity of 12 of the 13 active site substrate binding residues, and 83% overall sequence identity between T. cruzi and T. brucei CYP51 orthologues. This result is a striking indication of the sensitivity of CYP51 to alterations of the topography of its active site at position 78. The difference in position 78 is of functional importance, because phenylalanine at this site is strictly specific to protozoa and plant species metabolizing 4a-methylated sterols [18] . Interestingly, T. cruzi is the only protozoan where the corresponding position (position 105 according to T. cruzi numbering) is occupied by isoleucine. Consistent with this observation, CYP51 Tc is catalytically more closely related to its fungal and animal orthologues, preferentially converting 4a,bdimethylated sterol substrates [21] , whereas T. brucei CYP51 is strictly specific to 4a-methylated obtusifoliol and norlanosterol [33] . The proteobacterium Methylococcus capsulatus, known to synthesize sterols from squalene [34] , is the only other known organism having isoleucine in the CYP51 position corresponding to F78. Not surprising, compound 10 was inactive against T. brucei in inhibitory assays in vitro.
In humans and animals metabolizing 4a,b-dimethylated 24,25-dihydrolanosterol, position 78 is always occupied by leucine. Therefore, the F78L substitution in the CYP51 Mt binding site was examined and found to slightly increase binding affinities toward compounds 8 and 10, as opposed to the rest of the compounds whose binding affinities decreased (Fig. 2) . Although a single amino acid substitution does not by any means convert bacterial protein into its mammalian counterpart, this finding is consistent with lack of toxicity in mammalian cells at inhibitory concentrations, and supports the possibility of rational design of highly selective anti-protozoan CYP51 inhibitors. The latter is of particular pharmacological importance as far as host-pathogen cross-reactivity is concerned, since CYP51 is present in human host.
The increased binding affinities toward CYP51 Tc of all the compounds we tested may indicate more extensive involvement of the BC-loop and C helix in protein-inhibitor interactions in CYP51 Tc than in CYP51 Mt . Assuming that compound 8 binds CYP51 Tc in a similarly compact donut-like shape that fills the space adjacent to the porphyrin ring, its 300-fold increase in binding affinity could be achieved solely by stabilization of the BCregion of CYP51 Tc without engaging the species-specific cavity. This possibility opens the door to a rational design effort in which the beneficial features of both compounds 8 and 10 would be combined to yield third generation compounds that would more potently and selectively inhibit CYP51 Tc . Toward this end compound 10 is currently being evaluated in animal models of Chagas' disease.
